Abstract:Glycosylation is a tightly regulated post-translational modification where structured sugar groups are added to protein amino acid backbones, most commonly on asparagine for N-glycosylation. The glycosylation-regulating metabolic enzyme uridine diphosphate-glucose pyrophosphorylase 2 (UGP2) is required in oncogene-transformed cancer cells, but not in normal cells. UGP2 heavily regulates glycosylation of epidermal growth factor receptor (EGFR) at asparagine 361 (N361), a key site near the ligand binding domain. EGFR is a transmembrane tyrosine kinase receptor that promotes cell proliferation via growth cascades. Mutations and amplifications in EGFR account for a significant fraction of non-small cell lung carcinomas and breast adenocarcinoma, with L858R being the most common oncogenic hotspot. Other glycosylation sites on EGFR have been implicated in ligand binding, dimerization, and phosphorylation of downstream targets. Molecular dynamic simulations suggested that N361 may be important for dimerization or ligand binding. However, the functional relevance of how glycosylation of EGFR at N361 impacts EGFR protein and cellular behaviors remains unclear. To determine the functional relevance of glycosylation at N361, we created glycosylation-defective EGFR N361A mutant, with or without an additional oncogenic EGFR L858R mutant. We expressed these constructs in MCF10A and 293T cells, which do not have pre-existing activation of this pathway. Immunofluorescence and flow cytometry showed that the mutants were each well expressed at the cell membrane. Proximity ligation assays measuring dimerization of EGFR in cells showed that EGFR N361A greatly increased dimerization relative to wildtype controls. Loss of glycosylation of EGFR N361 impacted cell viability when grown in dose courses of its high affinity ligand EGF or lower affinity ligand amphiregulin. Furthermore, EGFR N361A desensitized cells expressing the oncogenic EGFR L858R to inhibitors targeting the extracellular domain, possibly because the mutation alters the antibody binding interface. N361A sensitized EGFR L858R to inhibitors targeting the cytoplasmic domain of EGFR. These findings help us understand the intricate relationship between EGFR and N-glycosylation, reinforcing the critical functional relevance of post-translational modifications on oncogenes. Citation Format: Dennis Lam, Ariel N. Liberchuk, Brandon Arroyo, Andrew L. Wolfe. Mechanistic effects of N361 glycosylation in epidermal growth factor receptor protein [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 4365.

N-Glycosylation of Integrin Α5 Acts As a Switch for EGFR-mediated Complex Formation of Integrin Α5β1 to Α6β4

O-GlcNAcylation regulates epidermal growth factor receptor intracellular trafficking and signaling

N-Glycosylation of the I-like Domain of β1 Integrin Is Essential for β1 Integrin Expression and Biological Function

Role of Site-Specific Glycosylation in the I-Like Domain of Integrin β1 in Small Extracellular Vesicle-Mediated Malignant Behavior and FAK Activation

N-glycosylation of the human neuropeptide QRFP receptor (QRFPR) is essential for ligand binding and receptor activation

Regulation on the expression and N-glycosylation of integrins by N-acetylglucosaminyltransferase V.

Functional effects of glycosylation at Asn-579 of the epidermal growth factor receptor

Effects of N361 Glycosylation on Epidermal Growth Factor Receptor Biological Function

N-glycosylation of α1D-adrenergic receptor N-terminal domain is required for correct trafficking, function, and biogenesis

Increase in β1-6 GlcNAc branching caused by N- acetylglucosaminyltransferase V directs integrin β1 stability in human hepatocellular carcinoma cell line SMMC-7721

N-acetylglucosaminyltransferase-I As a Novel Regulator of Epithelial-Mesenchymal Transition

Focal-adhesion kinase regulates the sialylation of N-glycans via the PI4KIIα-PI4P pathway

Novel regulatory mechanisms of N-glycan sialylation: Implication of integrin and focal adhesion kinase in the regulation

Crystal structure of α5β1 integrin ectodomain: Atomic details of the fibronectin receptor

Increased Integrin Α5β1 Heterodimer Formation and Reduced C‐jun Expression Are Involved in Integrin Β1 Overexpression‐mediated Cell Growth Arrest

A proteomics approach to isolating neuropilin-dependent α5 integrin trafficking pathways: neuropilin 1 and 2 co-traffic α5 integrin through endosomal p120RasGAP to promote polarised fibronectin fibrillogenesis in endothelial cells

The Role of Up-Regulation of Integrin Β1 in Resistance to Gefitinib in Non-Small Cell Lung Cancer

Abstract 4365: Mechanistic effects of N361 glycosylation in epidermal growth factor receptor protein

N-glycosylation of Siglec-15 Decreases Its Lysosome-Dependent Degradation and Promotes Its Transportation to the Cell Membrane.

N‐Glycosylation Affects the Adhesive Function of E‐Cadherin Through Modifying the Composition of Adherens Junctions (ajs) in Human Breast Carcinoma Cell Line MDA‐MB‐435

Glycosylation alters dimerization properties of a cell-surface signaling protein, CEACAM1